Novo Nordisk
Novo Nordisk A/S, a Danish pharmaceutical company, specializes in diabetes care, growth disorders, and hormone therapies globally.
Novo Nordisk A/S, a Danish pharmaceutical company, specializes in diabetes care, growth disorders, and hormone therapies globally.
novonordisk.comCrawled Oct 15, 2026
Novo Nordisk seeks qualified bachelor’s students, pre- and postgraduate master’s students, PhD students and postdocs, as well as medical doctors early in their careers.
Guided by the healthcare needs people have today and tomorrow. Novo offers a broad range of job opportunities across borders and job functions.
The Novo Nordisk Way is a values-based governance framework.
The company says more life-saving medicines need to reach vulnerable people and more needs to be done to stop the rise of chronic diseases.
The company has a history of innovation and focuses on helping people living with diabetes, obesity, haemophilia and growth disorders.
The company has expertise across the pharmaceutical value chain and collaborates with academia and biotech companies around the world to foster new innovations.
Novo Nordisk offers contact through local offices or corporate headquarters at +45 4444 8888, Novo Allé, 2880 Bagsvaerd, Denmark.
The page provides contact details for all Novo Nordisk offices, research centres and production facilities.
This webpage provides information on how people can apply for funding, sponsorships and grants from Novo Nordisk
Novo Nordisk says reports of product concerns or side effects help safeguard patient safety and ensure its medicines and devices remain reliable and effective.
The company says it combines more than a century of scientific expertise with an understanding of people’s lives to create treatments and support for serious chronic diseases.
CNBC's Morning Squawk highlights rising Treasury yields, Novo's struggle to reassure investors, Meta's consumer-AI push and increased spending on cat products. The 30-year Treasury yield reaches its highest level since 2004, while mortgage rates jump to 7.45%. Novo shares fall more than 10% for the week as Eli Lilly gains ground in oral obesity drugs, while Meta rises nearly 17% after unveiling its Muse Charm device; cat spending benefits Chewy, General Mills and Petco.
Sep 2026 · CNBC TechNews article
GitHubRepository owner